Innovative Drug Delivery Zosano Pharma specializes in proprietary transdermal systems designed for rapid, consistent drug delivery, which addresses unmet needs for fast-acting therapeutics. This focus presents an opportunity to collaborate on developing new formulations for existing drugs or expanding into additional therapeutic areas requiring quick onset of action.

Strategic Asset Sale The company sold its assets to Emergex Vaccines in late 2022, indicating a shift in corporate strategy towards licensing or partnership models rather than direct manufacturing. This transition can open doors for partners interested in licensing, co-development, or distribution of Zosano’s innovative delivery technology.

Recent Funding & Public Offering Having recently completed a $15.4 million public offering and secured initial funding, Zosano is positioned for potential growth and R&D expansion. Sales opportunities may exist in supplying components, technology integration, or joint research initiatives to support their pipeline development.

Focus on CNS and Vaccines Zosano's emphasis on central nervous system applications and COVID-19 vaccine candidates suggests a preference for collaborations in neurotherapeutics and vaccine delivery, which can be leveraged to identify partners seeking innovative administration systems for these large markets.

Market & Regulatory Environment Given the company’s brief history of market activity and recent news of financial valuations and strategic shifts, there is a significant opportunity to engage with Zosano on navigating regulatory pathways, clinical trials, and market entry strategies for new transdermal formulations, especially in high-growth therapeutic sectors.